Skip to main content
. 2019 Mar 5;19(2):e11. doi: 10.4110/in.2019.19.e11

Figure 2. IM156 dose-dependently impairs CD127 conversion of antigen-specific CD8+ T cells.

Figure 2

LCMV-infected mice were treated with various concentrations of IM156 from days −1 to 29 post-infection. (A) Representative plot showing the frequency of GP33 tetramer-positive cells among CD8+ or CD4+ T cells in PBMCs of IM156-treated mice at the indicated days post-infection. (B) Frequency of GP33+CD8+ T cells as in A. (C) Expression levels of CD127 (left), CD62L (middle), and KLRG1 (right) on tetramer-positive CD8+ T cells in PBMCs of IM156-treated mice at the indicated time post-infection. The relative percentages of CD127, CD62L, and KRLG1-expressing cells are indicated. (D) MFI of CD127 (top), CD62L (middle), and KLRG1 (bottom) on virus-specific CD8+ T cells in PBMCs as in C.

Data are representative of 3 independent experiments n=4–5 mice per group. Results are the mean ± SEM and statistical significance was determined by two-tailed unpaired Student's t-test.

*p<0.05; **p<0.01; ***p<0.001.